Compare Piramal Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AUROBINDO PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AUROBINDO PHARMA PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
 
P/E (TTM) x 13.7 10.6 129.5% View Chart
P/BV x 0.9 2.3 37.9% View Chart
Dividend Yield % 2.0 0.5 373.7%  

Financials

 PIRAMAL ENTERPRISES   AUROBINDO PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
AUROBINDO PHARMA
Mar-18
PIRAMAL ENTERPRISES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303809 408.2%   
Low Rs1,797504 356.5%   
Sales per share (Unadj.) Rs716.5281.1 254.9%  
Earnings per share (Unadj.) Rs79.741.4 192.7%  
Cash flow per share (Unadj.) Rs107.950.9 212.1%  
Dividends per share (Unadj.) Rs28.002.50 1,120.0%  
Dividend yield (eoy) %1.10.4 288.4%  
Book value per share (Unadj.) Rs1,477.5199.4 741.1%  
Shares outstanding (eoy) m184.45585.88 31.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.62.3 152.4%   
Avg P/E ratio x32.015.9 201.5%  
P/CF ratio (eoy) x23.612.9 183.1%  
Price / Book Value ratio x1.73.3 52.4%  
Dividend payout %35.16.0 581.1%   
Avg Mkt Cap Rs m470,292384,630 122.3%   
No. of employees `0007.817.3 45.1%   
Total wages/salary Rs m22,50421,308 105.6%   
Avg. sales/employee Rs Th16,899.49,500.7 177.9%   
Avg. wages/employee Rs Th2,877.71,229.4 234.1%   
Avg. net profit/employee Rs Th1,879.91,397.9 134.5%   
INCOME DATA
Net Sales Rs m132,153164,666 80.3%  
Other income Rs m3,1281,020 306.7%   
Total revenues Rs m135,281165,686 81.6%   
Gross profit Rs m66,29037,718 175.8%  
Depreciation Rs m5,2025,580 93.2%   
Interest Rs m44,097777 5,673.9%   
Profit before tax Rs m20,11932,380 62.1%   
Minority Interest Rs m3,19431 10,171.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6118,183 105.2%   
Profit after tax Rs m14,70124,229 60.7%  
Gross profit margin %50.222.9 219.0%  
Effective tax rate %42.825.3 169.4%   
Net profit margin %11.114.7 75.6%  
BALANCE SHEET DATA
Current assets Rs m122,742121,878 100.7%   
Current liabilities Rs m310,81086,806 358.1%   
Net working cap to sales %-142.321.3 -668.2%  
Current ratio x0.41.4 28.1%  
Inventory Days Days23130 17.8%  
Debtors Days Days3968 56.8%  
Net fixed assets Rs m116,90481,037 144.3%   
Share capital Rs m369586 63.0%   
"Free" reserves Rs m272,161116,218 234.2%   
Net worth Rs m272,530116,804 233.3%   
Long term debt Rs m270,1964,512 5,988.4%   
Total assets Rs m856,261211,052 405.7%  
Interest coverage x1.542.7 3.4%   
Debt to equity ratio x1.00 2,566.6%  
Sales to assets ratio x0.20.8 19.8%   
Return on assets %6.911.8 58.0%  
Return on equity %5.420.7 26.0%  
Return on capital %12.427.4 45.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20080,727 18.8%   
Fx outflow Rs m4,88934,700 14.1%   
Net fx Rs m10,31246,027 22.4%   
CASH FLOW
From Operations Rs m-115,97519,548 -593.3%  
From Investments Rs m-8,265-19,570 42.2%  
From Financial Activity Rs m107,5258,642 1,244.3%  
Net Cashflow Rs m-16,6508,922 -186.6%  

Share Holding

Indian Promoters % 52.9 54.1 97.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 8.0 50.3%  
FIIs % 26.6 27.7 96.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.2 161.8%  
Shareholders   93,274 69,601 134.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

AUROBINDO PHARMA Surges by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Oct 14, 2019 | Updated on Oct 14, 2019

AUROBINDO PHARMA share price has surged by 6% and its current market price is Rs 464. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 5.7%). The top losers are FDC LTD. and DIVIS LABORATORIES (down 0.3%).

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 14, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS